Ethics in phase II trials of cancer therapies.
نویسنده
چکیده
s.asp). FELLOWSHIPS: The Harvard Univer-sity Center for Ethics and the Pro-fessions invites applications for Faculty Fellowships in Ethics for the academic year 2002-2003. Fellow-ships will be awarded to outstanding teachers and scholars who wish to develop their ability to address questions of moral choice in such areas as business, education, government, law, medicine, and public policy. Fellows participate in the weekly seminar of the Center, which discusses problems of teaching and research in ethics. They have access to a wide range of activities in all of the professional schools at Harvard, as well as the Faculty of Arts and Sciences, including opportunities to participate in courses, colloquia, curricular development, collaborative research, study groups, case-writing workshops, and clinical programs. A significant part of their time is devoted to conducting their own research in ethics. The Fellowship extends from September through June. Applicants should hold a doctorate in philosophy, political theory, theology, or related disciplines, or a professional degree in business, education, public policy, law, or medicine. Preference will be given to applicants at an early stage in their careers, normally no more than ten years from the terminal degree in their field. The deadline for application: December 1, 2001. Con-tact: Center for Ethics and the Professions, Harvard University, 79 John F. Kennedy Street, Cambridge, MA 02138; ph. 617-4951336; fx. 617-496-6104; email: [email protected];website: http://www.ethics.harvard.edu. The University Center for Human Values supports teaching, research, and discussion of ethics and human values throughout the curriculum and across the disciplines at Princeton University. With seminar and lecture courses, public lectures and symposia, a publication series and the scholarly work of its faculty and visiting fellows, the University Center foster ongoing inquiry into important ethical issues in private and public life. The University Center invites applications from all disciplines for the Laurance S. Rockefeller Visiting Fellowships. These fellowships will be awarded for the academic year 2002-2003 to outstanding scholars and teachers interested in devoting a year in residence at Princeton writing about ethics and human values. A selection committee of University Center faculty evaluates applicants on the basis of: 1) the significance of their proposed research and its relevance to the purposes of the University Center, 2) the quality of their previous re-search and their ability to benefit from the activities of the University Center, and 3) the contribution they are likely to make to higher education in the future. Deadline: December 5, 2001. Contact: Amy Gutman, Director, University Center for Human Values, 304 Louis Marx Hall, Princeton University, Princeton, NJ 08544-1006, ph. 609-258-4798, email: [email protected]. The Center for the Study of Ethics in the Professions (CSEP) was established in 1976 for the purpose of promoting education and scholarship relating to ethical and policy issues of the professions. Perspectives on the Professions is one of the means the Center has of achieving that purpose. EDITOR: Michael Davis MANAGING EDITORS: Ethel Lewis EDITORIAL BOARD: David Beam, Robert F. Ladenson, Martin Malin, Ullica Segerstrale, Warren Schmaus CSEP DIRECTOR: Vivian Weil Opinions expressed in Perspectives on the Professions are those of the authors, and not necessarily those of the Center for the Study of Ethics in the Professions or the Illinois Institute of Technology.
منابع مشابه
New treatment modalities in advanced thyroid cancer.
BACKGROUND Thyroid cancer is a heterogeneous disease that is classified into differentiated thyroid carcinoma (DTC), undifferentiated/anaplastic thyroid carcinoma (ATC) and medullary thyroid carcinoma. Results of conventional treatment modalities in advanced thyroid cancer have been disappointing and therefore, new therapies are needed. METHODS We searched PubMed, The Cochrane Library, Medlin...
متن کاملAdaptive designs for Phase II oncology trials
The role of Phase II trials in oncology drug development Traditionally, Phase II in oncology drug development acts as a screening tool by identifying treatments with sufficient activity that warrant further investigation in large and costly Phase III studies. However, Phase II has also another more prominent role in cancer research as there is a significant number of drugs that were approved ba...
متن کاملClinical trials in New Zealand--treading water in the knowledge wave?
AIMS To describe the number and type of clinical trials in New Zealand 1998-2003, and to identify the number of trials for which approval was sought in 2003 that were listed with trial registries. METHODS Annual reports (1998-2003) from all regional ethics committees were reviewed for clinical trials. Trials must have been referred to as phase I, II, or III clinical trials; employ descriptors...
متن کاملEffective incorporation of biomarkers into phase II trials.
The incorporation of biomarkers into the drug development process will improve understanding of how new therapeutics work and allow for more accurate identification of patients who will benefit from those therapies. Strategically planned biomarker evaluations in phase II studies may allow for the design of more efficient phase III trials and better screening of therapeutics for entry into phase...
متن کاملThe future of systemic therapies for localised prostate cancer.
In the last decade, many systemic therapies have become available to improve survival in the setting of castration-resistant prostate cancer. Once effective treatments for advanced and incurable disease have been established, these agents are generally explored in the adjuvant and neoadjuvant settings to evaluate their role in increasing the chance of cure for localised disease. Clinical trials...
متن کاملAntiangiogenic therapies in epithelial ovarian cancer.
BACKGROUND Angiogenesis is a critical component of tumor development and proliferation, and increased angiogenesis has been associated with a worse clinical outcome in a number of solid tumors, including ovarian cancer. Therefore, agents that target the angiogenic process are of considerable interest in the treatment of ovarian cancer. METHODS Studies evaluating the efficacy of antiangiogenic...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Perspectives on the professions
دوره 20 1 شماره
صفحات -
تاریخ انتشار 2000